{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T16:26:28Z","timestamp":1787415988691,"version":"build-2736575974"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020581","name":"AIRC Italian Association for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ejca.2026.116937","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T06:25:56Z","timestamp":1784010356000},"page":"116937","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Chemotherapy type and survival in young BRCA1\/2 carriers with HER2-negative early breast cancer"],"prefix":"10.1016","volume":"245","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4068-9514","authenticated-orcid":false,"given":"Rinat","family":"Bernstein-Molho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tal","family":"Sella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Delucchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6443-8883","authenticated-orcid":false,"given":"Florence","family":"Coussy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee Jeong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Linn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Di Meglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9902-711X","authenticated-orcid":false,"given":"Katarzyna","family":"Pogoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ava","family":"Kwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0295-7511","authenticated-orcid":false,"given":"Elisa","family":"Agostinetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyoti","family":"Bajpai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannick","family":"Van Herck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2525-3787","authenticated-orcid":false,"given":"Alberta","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Balmana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7472-9350","authenticated-orcid":false,"given":"Halle C.F.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8227-8740","authenticated-orcid":false,"given":"Fedro A.","family":"Peccatori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann H.","family":"Partridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melina","family":"Winocur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiphaine","family":"Renaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7087-5687","authenticated-orcid":false,"given":"Christine","family":"Rousset-Jablonski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong Eon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Toss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shani","family":"Paluch-Shimon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie M.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4122-9624","authenticated-orcid":false,"given":"Alexios","family":"Matikas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3587-339X","authenticated-orcid":false,"given":"Cynthia","family":"Villarreal-Garza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1577-8176","authenticated-orcid":false,"given":"Claudio","family":"Vernieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8154-4848","authenticated-orcid":false,"given":"Minna","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6924-9467","authenticated-orcid":false,"given":"Deniz Can","family":"Guven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5077-6814","authenticated-orcid":false,"given":"Wanda","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn J.","family":"Ruddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3967-9861","authenticated-orcid":false,"given":"Maria Vittoria","family":"Dieci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5688-2194","authenticated-orcid":false,"given":"Robert","family":"Fruscio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"De Marchis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Kemp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3356-1969","authenticated-orcid":false,"given":"Pedro A.","family":"Meireles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"Razeti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Del Pilar","family":"Diz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8571-1148","authenticated-orcid":false,"given":"Shelley E.","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0573-4938","authenticated-orcid":false,"given":"Fabio","family":"Puglisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Clatot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rinat","family":"Yerushalmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Cichowska-Cwalinska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5481-4972","authenticated-orcid":false,"given":"Alessandra","family":"Chirco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"De Angelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9566-4579","authenticated-orcid":false,"given":"Eva","family":"Blondeaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Lambertini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2026.116937_bib1","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S0140-6736(11)61625-5","article-title":"Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100\u2008000 women in 123 randomised trials","volume":"379","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2026.116937_bib2","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/S0140-6736(23)00285-4","article-title":"Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials","volume":"401","year":"2023","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.ejca.2026.116937_bib3","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s40487-025-00332-8","article-title":"Oncotype DX Recurrence Score and Germline BRCA Variants in Patients with HR-Positive\/HER2-Negative Early Breast Cancer: A Retrospective Observational Study","volume":"13","author":"Morganti","year":"2025","journal-title":"Oncol Ther"},{"issue":"8","key":"10.1016\/j.ejca.2026.116937_bib4","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/cncr.29903","article-title":"Twenty-one-gene recurrence score assay in BRCA-associated versus sporadic breast cancers: Differences based on germline mutation status","volume":"122","author":"Shah","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2026.116937_bib5","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s10549-024-07271-4","article-title":"BRCA1\/2 mutation carriers vs the general breast cancer population (N\u2009=\u2009799,986): 21-gene assay-based molecular characterization","volume":"206","author":"Yerushalmi","year":"2024","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejca.2026.116937_bib6","doi-asserted-by":"crossref","first-page":"8412","DOI":"10.1245\/s10434-023-14319-0","article-title":"Mutational Status is Associated with a Higher Rate of Pathologic Complete Response After Neoadjuvant Chemotherapy in Hormone Receptor-Positive Breast Cancer","volume":"30","author":"Myers","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2026.116937_bib7","first-page":"1619","article-title":"Personalizing Neoadjuvant Chemotherapy: The Impact of BRCA Variants on Pathologic Complete Response in Luminal B Breast Cancer","volume":"17","author":"Di Leone","year":"2025","journal-title":"Cancers Multidiscip Digit Publ Inst"},{"key":"10.1016\/j.ejca.2026.116937_bib8","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.breast.2018.05.007","article-title":"Evaluation of tolerability and efficacy of incorporating carboplatin in neoadjuvant anthracycline and taxane based therapy in a BRCA1 enriched triple-negative breast cancer cohort","volume":"40","author":"Sella","year":"2018","journal-title":"Breast"},{"key":"10.1016\/j.ejca.2026.116937_bib9","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1002\/ijc.33234","article-title":"Impact of the addition of carboplatin to anthracycline-taxane-based neoadjuvant chemotherapy on survival in BRCA1\/2-mutated triple-negative breast cancer","volume":"148","author":"Zhang","year":"2021","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2026.116937_bib10","first-page":"2341","article-title":"Survival analysis of carboplatin added to an anthracycline\/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response\u2014final results from GeparSixto","volume":"29","author":"Loibl","year":"2018"},{"key":"10.1016\/j.ejca.2026.116937_bib11","first-page":"7","article-title":"Moment of truth-adding carboplatin to neoadjuvant\/adjuvant chemotherapy in triple negative breast cancer improves overall survival: An individual participant data and trial-level Meta-analysis","volume":"64","author":"Pathak","year":"2022","journal-title":"Breast J Eur Soc Mastology"},{"key":"10.1016\/j.ejca.2026.116937_bib12","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1200\/JCO.2014.57.0572","volume":"33","author":"Sikov","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116937_bib13","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1093\/annonc\/mdy127","article-title":"Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis","volume":"29","author":"Poggio","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.116937_bib14","first-page":"139","article-title":"Exploiting the DNA Repair Defect in BRCA Mutant Cells in the Design of New Therapeutic Strategies for Cancer","volume":"70","author":"Tutt","year":"2005"},{"key":"10.1016\/j.ejca.2026.116937_bib15","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/s41591-018-0009-7","article-title":"A randomised phase III trial of carboplatin compared with docetaxel in BRCA1\/2 mutated and pre-specified triple negative breast cancer \u201cBRCAness\u201d subgroups: the TNT Trial","volume":"24","author":"Tutt","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2026.116937_bib16","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1200\/JCO.19.03292","article-title":"TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial)","volume":"38","author":"Tung","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116937_bib17","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s10549-014-3100-x","article-title":"Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients","volume":"147","author":"Byrski","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejca.2026.116937_bib18","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1001\/jamaoncol.2017.1007","article-title":"Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial","volume":"3","author":"Hahnen","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2026.116937_bib19","first-page":"497","article-title":"Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial","volume":"19","author":"Loibl","year":"2018"},{"key":"10.1016\/j.ejca.2026.116937_bib20","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s41523-021-00349-y","article-title":"Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness","volume":"7","author":"Metzger-Filho","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.ejca.2026.116937_bib21","doi-asserted-by":"crossref","unstructured":"Felsheim B.M., Nekljudova V., Carey L.A., et al. Pooled analysis of the BrighTNess, CALGB 40603 (Alliance), and GeparSixto clinical trials identifies the impact of neoadjuvant carboplatin on pCR and survival in early-stage triple-negative breast cancer. Presented at SABCS 2025. December 9-12, 2025. San Antonio, Texas. Abstract RF2-02. [Internet]. 2025 [cited 2026 Jan 15]. https:\/\/sabcs.org\/events\/2025\/rapid-fire-2\/. Accessed 15 Jan 2026.","DOI":"10.1158\/1557-3265.SABCS25-RF2-02"},{"issue":"6","key":"10.1016\/j.ejca.2026.116937_bib23","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMoa2112651","article-title":"KEYNOTE-522 Investigators. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer","volume":"386","author":"Schmid","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116937_bib24","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/jama.2023.25463","article-title":"Pregnancy After Breast Cancer in Young BRCA Carriers: An International Hospital-Based Cohort Study","volume":"331","author":"Lambertini","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.ejca.2026.116937_bib25","first-page":"759","article-title":"Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: an international cohort study","volume":"26","author":"Blondeaux","year":"2025"},{"key":"10.1016\/j.ejca.2026.116937_bib26","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1200\/JCO.20.03613","article-title":"Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0","volume":"39","author":"Tolaney","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116937_bib27","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1200\/JCO-24-01334","article-title":"Clinical Behavior of Breast Cancer in Young BRCA Carriers and Prediagnostic Awareness of Germline BRCA Status","volume":"43","author":"Lambertini","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116937_bib28","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1001\/jamaoncol.2023.5033","article-title":"Clinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in Triple-Negative Breast Cancer","volume":"10","author":"Sharma","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2026.116937_bib29","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1093\/oncolo\/oyad139","article-title":"Neoadjuvant Talazoparib in Patients With Germline BRCA1\/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study","volume":"28","author":"Litton","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2026.116937_bib30","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.annonc.2022.09.159","article-title":"Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1\/2 and high-risk, early breast cancer","volume":"33","author":"Geyer","year":"2022","journal-title":"Ann Oncol J Eur Soc Med Oncol"},{"key":"10.1016\/j.ejca.2026.116937_bib31","unstructured":"Tung N., Stradella A., Brufsky A., et al. OlympiA-N: a phase 2, multicenter, open-label study to assess the efficacy and safety of neoadjuvant olaparib monotherapy and olaparib plus durvalumab in patients with BRCA mutations and early-stage HER2-negative breast cancer. Presented at SABCS 2025. December 9-12, 2025. San Antonio, Texas. Abstract RF2-02. October 8, 2025. Abstract RF5-03. Accessed January 16, 2026. https:\/\/sabcs.org\/events\/2025\/rapid-fire-5\/ [Internet]. 2025 [cited 2026 Jan 16]."},{"key":"10.1016\/j.ejca.2026.116937_bib32","doi-asserted-by":"crossref","unstructured":"Johnston S., Martin M., O\u2019Shaughnessy J., Hegg R., Tolaney S.M., Guarneri V., et al. Overall survival with abemaciclib in early breast cancer \u2729. Ann Oncol [Internet]. Elsevier; 2025 [cited 2025 Dec 3];0. https:\/\/doi.org\/10.1016\/j.annonc.2025.10.005.","DOI":"10.1016\/j.annonc.2025.10.005"},{"key":"10.1016\/j.ejca.2026.116937_bib33","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/oncolo\/oyad123","article-title":"Adjuvant Olaparib for Germline BRCA Carriers With HER2-Negative Early Breast Cancer: Evidence and Controversies","volume":"28","author":"Morganti","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2026.116937_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.102887","article-title":"Current controversies in the use of Oncotype DX in early breast cancer","volume":"135","author":"Berton Giachetti","year":"2025","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejca.2026.116937_bib35","doi-asserted-by":"crossref","DOI":"10.1177\/17588359251368733","article-title":"Early breast cancer in young BRCA carriers: from diagnosis to treatment and survivorship","volume":"17","author":"Borea","year":"2025","journal-title":"Ther Adv Med Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926007185?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926007185?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T16:19:02Z","timestamp":1787415542000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926007185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":34,"alternative-id":["S0959804926007185"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116937","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chemotherapy type and survival in young BRCA1\/2 carriers with HER2-negative early breast cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116937","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"116937"}}